Taco Bell has 6 new beverages. What are Refrescas?
The company announced on June 26 it was introducing new beverages called Refrescas to menus nationwide. According to the chain, the drinks are crafted to "quench every kind of craving – whether you're seeking a refreshing sip, an energizing boost or a frozen escape."
The six drinks include three refreshers, two energy drinks and a cooling freeze. According to Taco Bell, the three Agua Refrescas join menus permanently after initially being tested in Southern California in 2024, with a positive response.
Here's what to know about the new Taco Bell beverages.
What are Taco Bell's Refrescas? List of new beverages
Taco Bell's full lineup of Refrescas includes:
How much are Taco Bell Refrescas?
The Agua Refrescas cost $3.99 for a 20-ounce drink while the Rockstar Energy Refrescas cost $4.49 for a 20-ounce beverage. The Refrescas Freezes are available in a 16-ounce or 20-ounce option and cost $3.79 and $3.99, respectively.
Why is Taco Bell adding Refrescas to the menu?
Taco Bell is seemingly going after younger consumers searching for fresh beverage options.
'We're seeing today that people, especially younger consumers, are reaching for refreshing drinks as part of their lifestyle, whether it's for energy or a sweet treat throughout the day,' said Liz Matthews, Taco Bell's Global Chief Food Innovation Officer, in the June 26 news release. 'So, we're making big investments to become the ultimate beverage stop where our fans can expect to see the same bold, unexpected creativity in their cups as they do on their plates.'
Taco Bell Refrescas do contain caffeine ranging from 52 mg to 200 mg. Healthy adults can generally consume up to 400 mg of caffeine per day without negative affects, according to the FDA. However, the FDA warns about heavy consumption of caffeine among children. "Too much caffeine in children and teens can cause increased heart rate, heart palpitations, high blood pressure, anxiety, and lead to sleep problems, digestive problems and dehydration," the FDA says.
Taco Bell also debuts Crispy Chicken Tacos, Burritos and Strips
In addition to the new beverages, Taco Bell also announced last month that Crispy Chicken Tacos and Burritos will be available at locations nationwide for a limited time.
Both items feature a Crispy Chicken Strip inside and are available with new Spicy Ranchero and Avocado Ranch sauces.
For $2.79, the Crispy Chicken Tacos layers its new crispy strip with purple cabbage, lettuce, pico de gallo and shredded cheddar cheese. Meanwhile, the Crispy Chicken Burrito includes two strips, purple cabbage, crisp lettuce, pico de gallo and cheddar cheese for $5.49.
The chain is also offering two Crispy Chicken Strips for the price of $3.99, not to be confused with its Crispy Chicken Nuggets, which debuted last December and returned in April.
Contributing: Anthony Robledo, USA TODAY
Gabe Hauari is a national trending news reporter at USA TODAY. You can follow him on X @GabeHauari or email him at Gdhauari@gannett.com.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Newsweek
an hour ago
- Newsweek
FDA Issues Bread Recall Update After Glass Discovered in Crusts
Based on facts, either observed and verified firsthand by the reporter, or reported and verified from knowledgeable sources. Newsweek AI is in beta. Translations may contain inaccuracies—please refer to the original content. The U.S. Food and Drug Administration (FDA) has ended a voluntary recall of 800 items after glass fragments were discovered in the crusts of several breads. Maryland-based Upper Crust Bakery LP initiated the recall regarding products distributed to six states: Pennsylvania, California, Connecticut, Maryland, Delaware, and Ohio. Upper Crust Bakery LP, operating out of Glenn Dale, voluntarily recalled three varieties of bread—Ancient Grains Hoagie Roll, Multigrain Sourdough, and Whole Grain Multigrain—after a team member discovered a glass fragment on a piece of seeded bread. The recall initially began on April 12, 2025, and the FDA classified it as Class II on April 25, the second-highest of three risk levels, which indicates the potential for temporary or reversible health consequences. The FDA terminated the recall on July 15. Stock image of sourdough bread slices. Stock image of sourdough bread slices. Getty Images Why it Matters The FDA warned that consuming glass fragments could cause injuries ranging from cuts in the mouth and throat to intestinal perforation—a risk prompting significant public attention. What To Know According to FDA records, the recall covered three products: Ancient Grains Hoagie Roll , 4 oz, Lot #90, 89 cases, carton code CP45, distributed frozen , 4 oz, Lot #90, 89 cases, carton code CP45, distributed frozen Multigrain Sourdough , 18 oz, Lot #90, 699 cases, carton code CP12, distributed frozen , 18 oz, Lot #90, 699 cases, carton code CP12, distributed frozen Whole Grain Multigrain, 20 oz, Lot #92, 30 cases, carton code CP12, distributed frozen The bakery, operating as Crest Hill Bakery, notified the FDA after an employee discovered a glass fragment during a routine inspection. Further investigation traced the source of the glass to sunflower seeds provided by supplier Magic Flame. Upper Crust Bakery LP stated that it immediately ceased using ingredients from the implicated supplier and removed all affected products from circulation. "We have ceased the use of sunflower seeds from the manufacturer associated with the glass fragments, Magic Flame," the company said in a statement announcing the recall. For consumers, the FDA and Upper Crust Bakery LP advised that bread with affected lot numbers should not be consumed but instead discarded or returned to the point of purchase for a refund. Health experts emphasized contacting a health care provider if glass ingestion is suspected due to the risk of gastrointestinal injury. Who People Are Saying Upper Crust Bakery LP, in a statement announcing the recall: "The recall was initiated after a vigilant team member discovered a small glass fragment on top of a piece of seeded bread." "We remain steadfast in our commitment to upholding the highest standards of quality and safety in all our products," the company added. The FDA warned at the time: "The agency warns that consuming glass fragments can result in significant injuries such as damage to teeth, lacerations of the mouth and throat, or perforation of the intestine." What Happens Next With the recall terminated as of July 15, 2025, Upper Crust Bakery LP stated that it has stopped sourcing sunflower seeds from the implicated supplier and has amended its food safety checks. For further updates on food recalls and safety guidance, visit the FDA's official recall search portal.
USA Today
an hour ago
- USA Today
Ice cream bars sold in 23 states recalled over listeria risk
More than 100,000 ice cream bars produced by Rich's Ice Cream have been recalled over concerns of potential listeria contamination. The Food and Drug Administration Authority (FDA) announced July 17 that Florida-based Rich's Ice Cream Co. is recalling select products due to potential listeria monocytogenes contamination. The recall, which impacts lot number 24351 through lot 25156 was initiated on June 27, according to the FDA notice and is classified as Class II with a total of 110,292 cases potentially affected. A Class II recall is "a situation in which use of, or exposure to, a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote," the FDA website states. USA TODAY was unable to reach Rich's Ice Cream for comment on July 21. Which Rich Ice Cream products are included in the recall? See list The affected products, sold in multiple states, according to the FDA advisory, include: The frozen treats were individually packaged in plastic bags and sold in master cases. More recalls: Ford, Mercedes-Benz, Jaguar among over 738,000 vehicles recalled: Check car recalls Which states are impacted by the recall? See list The affected products were distributed across 23 states, according to the FDA notice, including: They were also sold in Nassau, the capital of The Bahamas. What should you do if you purchased the affected products? FDA and Rich Ice Cream Co. have not yet specified what remedies are available for customers. Rich Ice Cream Co. did not immediately reply to USA TODAY's request for a statement and more information on the recall. Customers, meanwhile, can visit Rich Ice Cream Co.'s website for more information and to contact the company. Listeria poisoning symptoms Listeriosis, or listeria poisoning, is a foodborne bacterial infection most commonly caused by the bacterium listeria monocytogenes, according to the Centers for Disease Control and Prevention. It is considered a serious condition and can be dangerous or life-threatening, especially to older adults, people with weak immune systems, and pregnant women. Listeria is the third leading cause of death from foodborne illness in the U.S., according to the CDC. The agency estimates that the disease impacts 1,600 Americans each year, with approximately 260 people dying from those infections. Symptoms include, per the CDC: People in higher-risk categories who experience flu-like symptoms within two months after eating contaminated food should seek medical care. Contributing: Natalie Neysa Alund, USA TODAY Saman Shafiq is a trending news reporter for USA TODAY. Reach her at sshafiq@ and follow her on X and Instagram @saman_shafiq7.
Business Wire
an hour ago
- Business Wire
Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm Encourages Biohaven Ltd. (BHVN) Investors To Inquire About Securities Fraud Class Action
LOS ANGELES--(BUSINESS WIRE)--Glancy Prongay & Murray LLP, a leading national shareholder rights law firm, announces that a securities fraud class action lawsuit has been filed on behalf of investors who purchased or otherwise acquired Biohaven Ltd. ('Biohaven' or the 'Company') (NYSE: BHVN) securities between March 24, 2023 and May 14, 2025, inclusive (the 'Class Period'). Biohaven investors have until September 12, 2025 to file a lead plaintiff motion. IF YOU SUFFERED A LOSS ON YOUR BIOHAVEN LTD. (BHVN), CLICK HERE TO INQUIRE ABOUT POTENTIALLY PURSUING CLAIMS TO RECOVER YOUR LOSS UNDER THE FEDERAL SECURITIES LAWS What Happened? On July 17, 2023, Biohaven disclosed that the FDA had rejected the New Drug Application ('NDA') for its spinocerebellar ataxia ('SCA') treatment, troriluzole, having refused to even review the application after the Phase 3 SCA Trial had failed to meet its primary endpoint. On this news, Biohaven's stock price fell $5.38, or 22.6%, to close at $18.42 per share on July 27, 2023, thereby injuring investors. Then, on March 3, 2025, Biohaven released its fourth quarter and full year 2024 financial results, disclosing that recent data from a late-stage study of its BHV-7000 treatment for bipolar mania 'did not statistically separate from the comparator on the Young Mania Rating Scale primary outcome measure[.]' On this news, Biohaven's stock price fell $5.12, or 13.8%, to close at $32.06 per share on March 3, 2025. Then, on April 25, 2025, news reports emerged that, according to the European Medicines Agency ('EMA'), Biohaven had withdrawn its Marketing Authorization Application ('MAA') for troriluzole in late March 2025. On this news, Biohaven's stock price fell $3.56, or 15.2%, to close at $19.84 per share on April 25, 2025. Then, on May 14, 2025, Biohaven announced that 'the Division of Neurology 1 within FDA's Office of Neuroscience informed the Company that they are extending the [Prescription Drug User Fee Act ('PDUFA')] date for the troriluzole [NDA] for the treatment of [SCA] by three months to provide time for a full review of Biohaven's recent submissions related to information requests from the FDA,' and that '[t]he Division also informed Biohaven that it is currently planning to hold an advisory committee meeting to discuss the application, but no date has been scheduled.' On this news, Biohaven's stock price fell $3.84, or 19.5%, to close at $15.82 per share on May 15, 2025, thereby injuring investors further. What Is The Lawsuit About? The complaint filed in this class action alleges that throughout the Class Period, Defendants made materially false and/or misleading statements, as well as failed to disclose material adverse facts about the Company's business, operations, and prospects. Specifically, Defendants failed to disclose to investors that: (1) troriluzole's regulatory prospects as a treatment for SCA, and/or the sufficiency of data that Biohaven submitted in support of troriluzole's regulatory approval for this indication, were overstated; (2) BHV-7000's efficacy and clinical prospects as a treatment for bipolar disorder were likewise overstated; (3) all the foregoing, once revealed, was likely to have a significant negative impact on Biohaven's business and financial condition; and (4) as a result, Defendants' positive statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis at all relevant times. If you purchased or otherwise acquired Biohaven securities during the Class Period, you may move the Court no later than September 12, 2025 to request appointment as lead plaintiff in this putative class action lawsuit. Contact Us To Participate or Learn More: If you wish to learn more about this action, or if you have any questions concerning this announcement or your rights or interests with respect to these matters, please contact us: Charles Linehan, Esq., Glancy Prongay & Murray LLP, 1925 Century Park East, Suite 2100, Los Angeles California 90067 Email: shareholders@ Telephone: 310-201-9150, Toll-Free: 888-773-9224 Visit our website at Follow us for updates on LinkedIn, Twitter, or Facebook. If you inquire by email, please include your mailing address, telephone number and number of shares purchased. To be a member of the Class you need not take any action at this time; you may retain counsel of your choice or take no action and remain an absent member of the Class. This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.
